Gökhan UYANIK

Dr. Gökhan UYANIK

Department of Obstetrics and Gynaecology, Hatay Mustafa Kemal University, Hatay, Turkey (Türkiye)
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2024 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
PDF file
İGİSHAK GÖKÇEK
İSHAK GÖKÇEK
Gökhan UYANIKGökhan UYANIK
Gökhan UYANIK
TTTolga Tutar
Tolga Tutar
AGAhmet Gözer
Ahmet Gözer

29 April 2025 in Veterinary Sciences and Practices
Verified
Journal Article
Open access
PDF file
İGİSHAK GÖKÇEK
İSHAK GÖKÇEK
Gökhan UYANIKGökhan UYANIK
Gökhan UYANIK
This study investigated the protective effects of thymol on LPS-induced ovarian damage. Female Wistar albino rats were divided into five groups (n=35, group=7): control, solvent, LPS, thymol, and LPS+thymol. At the end of the study, hormone (E2 and AMH), oxidative stress (MDA, GSH, GSH-Px and catalase), and inflammatory cytokine (TNF-α and IL-6) analyses were performed in the samples taken from the animals. Ovary and body weights were also measured. Lipopolysaccharide treatment caused decreases in E2 AMH, GSH, GSH-Px and catalase levels but increased MDA, TNF-α and IL-6 levels. In the Lps+thymol group, thymol administration caused increases in E2, AMH, GSH, GSH-Px and catalase levels and decreased MDA, TNF-α and IL-6 levels. In conclusion, thymol administration positively affected Lps-induced hormonal, oxidative stress and inflammatory changes via antioxidant and anti-inflammatory mechanisms. However, it is thought that the long-term effects of thymol need to be demonstrated, especially by further molecular mechanisms.

19 September 2024 in Revista Científica de la Facultad de Ciencias Veterinarias
Verified
Journal Article
Open access
PDF file
İGİSHAK GÖKÇEK
İSHAK GÖKÇEK
AGAhmet Gözer
Ahmet Gözer
TKTuncer Kutlu
Tuncer Kutlu
MGMehmet Güvenç
Mehmet Güvenç
LALeyla Aydın
Leyla Aydın
Gökhan UYANIKGökhan UYANIK
Gökhan UYANIK
Ovarian cancer is a widespread type of cancer among gynecologic cancers and has a very high mortality rate. For this reason, the search for new treatments continues. Tyrosol is a phenolic compound with antioxidant and anti–inflammatory activity. The study, it was investigated the effect of Tyrosol on oxidative stress and inflammatory parameters in cisplatin–induced ovarian inflammation and oxidative stress in rats. For this purpose, twenty–four female Wistar albino rats were divided into four groups: control, Cisplatin, Tyrosol, and Cisplatin+Tyrosol. Cisplatin was administered intraperitoneally at 6 mg·kg-1 twice, once a week. Tyrosol (20 mg·kg-1) was administered daily by oral gavage for fourteen d. Oxidative stress and inflammatory biomarkers were measured in ovarian tissue. Cisplatin administration increased Malondialdehyde (MDA), tumor necrosis factor alpha (TNF–α), interleukin 6 (IL–6), and interleukin 1 beta (IL–1β) levels in the ovaries, while Glutathione (GSH), Glutathione Peroxidase (GSH–Px), and Catalase levels were decreased. Tyrosol administration was shown to decrease oxidative stress parameters and inflammatory cytokines. In conclusion, it can be say that the protective activity of Tyrosol against Cisplatin–Induced ovarian inflammation and oxidative stress is realised through antioxidant and anti–inflammatory mechanisms.


1 June 2021 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
JFJ. Feurstein
J. Feurstein
MBMartina Behanova
Martina Behanova
Judith HaschkaJudith Haschka
Judith Haschka
KRK. Roetzer
K. Roetzer
Gökhan UYANIKGökhan UYANIK
Gökhan UYANIK
RKRoland Kocijan
Roland Kocijan
Background: The most frequent manifestation in adult Hypophosphatasia (HPP) is musculoskeletal pain.1,2 The unspecific nature of its clinical presentation may prevent correct diagnosis.3 Objectives: Identifying adult hypophosphatasia in the rheumatology unit. Methods: Over a period of 10 years 9,522 patients were screened in a rheumatological outpatient unit. Serum ALP levels ≤ 40 U/l were found in 524 patients. After screening for secondary causes, 73 patients were invited for clinical evaluation. Genetic testing was performed in 23 patients with suspected HPP. Logistic regression models were used to estimate the association of each clinical factor with HPP. Results: Mutations in the ALPL gene were observed in 57% of genetically screened patients. Arthralgia, fractures and pain were the leading symptoms in HPP patients. Chondrocalcinosis (OR 29.12; 95% CI 2.02-1593.52) and dental disease (OR 8.33; 95% CI 0.93-143.40) were associated with HPP independent of BMI. Onset of symptoms in HPP was at 35.1 (14.3) years, with a mean duration from symptoms to diagnosis of 14.4 (8.1) years. Bone mineral density (BMD) and trabecular bone score (TBS) as well as bone turnover markers were not indicative for HPP. Conclusion: HPP can mimic joint diseases.4 Thus, in patients with uncertain rheumatologic complaints and low ALP, HPP should be considered as potential diagnosis. References: [1]Durrough C, Colazo JM, Simmons J, et al. Characterization of physical, functional, and cognitive performance in 15 adults with hypophosphatasia. Bone 2021;142:115695. [2]Seefried L, Kishnani PS, Moseley S, et al. Pharmacodynamics of asfotase alfa in adults with pediatric-onset hypophosphatasia. Bone 2021;142:115664. [3]Högler W, Langman C, Gomes da Silva H, et al. Diagnostic delay is common among patients with hypophosphatasia: initial findings from a longitudinal, prospective, global registry. BMC musculoskeletal disorders 2019;20(1):80. [4]Seefried L, Dahir K, Petryk A, et al. Burden of Illness in Adults With Hypophosphatasia: Data From the Global Hypophosphatasia Patient Registry. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 2020;35(11):2171-78. Disclosure of Interests: None declared.